Publications by authors named "Gael Fortin"
Background: Cytoplasmic mislocalization and aggregation of TAR DNA-binding protein-43 (TDP-43) is a hallmark of the amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD) disease spectrum, causing both nuclear loss-of-function and cytoplasmic toxic gain-of-function phenotypes. While TDP-43 proteinopathy has been associated with defects in nucleocytoplasmic transport, this process is still poorly understood. Here we study the role of karyopherin-β1 (KPNB1) and other nuclear import receptors in regulating TDP-43 pathology.
View Article and Find Full Text PDFA multistage model instructed by a large dataset (knowledge bank [KB] algorithm) has recently been developed to improve outcome predictions and tailor therapeutic decisions, including hematopoietic stem cell transplantation (HSCT) in acute myeloid leukemia (AML). We assessed the performance of the KB in guiding HSCT decisions in first complete remission (CR1) in 656 AML patients younger than 60 years from the ALFA-0702 trial (NCT00932412). KB predictions of overall survival (OS) were superior to those of European LeukemiaNet (ELN) 2017 risk stratification (C-index, 68.
View Article and Find Full Text PDFArticle Synopsis
- Researchers are studying how metabolic changes, particularly in amino acid pathways linked to the folate cycle, affect the effectiveness of cancer treatments in acute myeloid leukemia (AML).
- They found that lower levels of folate and a specific gene variant affecting the MTHFR enzyme can lead to resistance against certain cancer therapies targeting MYC in both lab models and patient samples.
- Supplementing with CH-THF, a product of the MTHFR enzyme, can potentially overcome this resistance, suggesting that assessing individual folate cycle status may help identify patients who could benefit most from MYC-targeting treatments.